Navigation Links
AutoImmune Inc. Reports 2009 First Quarter Financial Results
Date:5/7/2009

PASADENA, Calif., May 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $170,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2009, compared with a net loss of $107,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2008. As of March 31, 2009, the Company reported $8.5 million in cash and marketable securities, the same amount reported as of December 31, 2008.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales in the first quarter of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the fourth quarter of 2008 and from the first quarter of 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide (formerly referred to as MBP8298), if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. The FDA has granted the product fast track designation. We expect final trial data will be available during the second half of 2009 from the first of two ongoing Phase III trials of dirucotide for the treatment of secondary progressive multiple sclerosis. We expect results from the second Phase III trial should be available during the last half of 2010.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

                            - Financial Chart Follows -



                                  AUTOIMMUNE INC.
                              STATEMENT OF OPERATIONS
                                    (Unaudited)

                                                           Three months ended
                                                                March 31,
                                                            2008        2009
                                                            ----        ----

      Revenue                                            $67,000    $104,000
                                                         -------    --------


      Costs and expenses:
        Cost of goods sold                                12,000      20,000
        Research and development                          42,000      71,000
        General and administrative                       205,000     188,000
                                                         -------     -------
          Total costs and expenses                       259,000     279,000
                                                         -------     -------

      Interest income                                     84,000       9,000
                                                          84,000       9,000
                                                          ------       -----

      Net loss                                          (108,000)   (166,000)
        Net income (loss) attributable to
         noncontrolling interest                           1,000      (4,000)
                                                           -----      ------

      Net loss attributable to AutoImmune Inc          ($107,000)  ($170,000)
                                                       =========   =========

      Net loss per share - basic                          ($0.01)     ($0.01)
                                                          ======      ======

      Net loss per share - diluted                        ($0.01)     ($0.01)
                                                          ======      ======

      Weighted average common shares
        outstanding - basic                           16,997,205  16,999,623
                                                      ==========  ==========

      Weighted average common shares
        outstanding - diluted                         16,997,205  16,999,623
                                                      ==========  ==========




                              CONDENSED BALANCE SHEET
                                    (Unaudited)

                                                    December 31,   March 31,
                                                        2008        2009
                                                        ----        ----


      Cash and marketable securities                  $8,475,000  $8,463,000
      Other current assets                               195,000     148,000

        Total assets                                  $8,670,000  $8,611,000
                                                      ==========  ==========

      Current liabilities                               $147,000    $228,000
      Total equity                                     8,523,000   8,383,000
                                                       ---------   ---------

      Total liabilities and equity                    $8,670,000  $8,611,000
                                                      ==========  ==========


'/>"/>
SOURCE Autoimmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
4. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
6. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
7. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Business Development, Europe. Based in Paris, he will focus on acquiring new accounts ... are being met. , “Fred brings to our European clients more ...
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/8/2016)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... technology companies in the TSX Venture 50 TM . ... the TSX Venture Exchange, in each of five major industry ... & life sciences, diversified industries and technology – based on ... investment, market cap growth, trading volume and analyst coverage. All ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):